S&P 500 Futures
(0.08%) 5 331.50 points

Dow Jones Futures
(0.01%) 40 142 points

Nasdaq Futures
(0.12%) 18 659 points

Oil
(-0.06%) $80.01

Gas
(0.50%) $2.64

Gold
(1.09%) $2 443.80

Silver
(2.79%) $32.13

Platinum
(0.32%) $1 093.50

USD/EUR
(-0.03%) $0.920

USD/NOK
(-0.05%) $10.67

USD/GBP
(0.02%) $0.787

USD/RUB
(-0.28%) $90.72

Realtime updates for Aligos Therapeutics, Inc. [ALGS]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Last Updated17 May 2024 @ 16:00

25% discount on Stockinvest.us - Use code: Podcast

5.11% $ 0.689

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases...

Stats
Today's Volume	884 252
Average Volume	410 403
Market Cap	51.65M
EPS	$0 ( 2024-05-07 )
Next earnings date	( $-0.160 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.510
ATR14	$0.00900 (1.29%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Mcclure Matthew W.	Buy	72 000	Stock Option (Right to Buy)
2024-03-01	Calhoun Lesley Ann	Buy	308 940	Stock Option (Right to Buy)
2024-03-01	Symons Julian A.	Buy	72 000	Stock Option (Right to Buy)
2024-03-01	Blatt Lawrence	Buy	965 435	Stock Option (Right to Buy)
2024-02-28	Hirth Peter	Buy	4 411	Stock Option (Right to Buy)

INSIDER POWER
82.19
Last 96 transactions
Buy: 18 924 669 \| Sell: 1 675 487

Volume Correlation

Long: -0.43 (neutral)

Short: -0.18 (neutral)

Signal:(53.08) Neutral

Aligos Therapeutics, Inc. Correlation

10 Most Positive Correlations
CRTD	0.856
BRKR	0.855
APLT	0.843
HCSG	0.842
TRMB	0.837
QRTEA	0.83
NOTV	0.828
TARA	0.827
OCUL	0.823
ACST	0.821

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aligos Therapeutics, Inc. Correlation - Currency/Commodity

0.02
( neutral )

0.17
( neutral )

0.00
( neutral )

0.00
( neutral )

0.00
( neutral )

0.11
( neutral )

Aligos Therapeutics, Inc. Financials

Annual	2023
Revenue:	$15.53M
Gross Profit:	$12.46M (80.24 %)
EPS:	$-1.360

FY	2023
Revenue:	$15.53M
Gross Profit:	$12.46M (80.24 %)
EPS:	$-1.360

FY	2022
Revenue:	$13.91M
Gross Profit:	$10.23M (73.57 %)
EPS:	$-2.25

FY	2021
Revenue:	$4.36M
Gross Profit:	$4.36M (100.00 %)
EPS:	$-3.22

Financial Reports:

No articles found.

Aligos Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Investing in the stock market involves risk and the value of your investment can fluctuate. The stock market can be affected by a variety of factors, including economic conditions, company performance, and global events. There is no guarantee of profit and you could lose money. Please consider your financial situation, investment goals, and level of risk tolerance before making any investment decisions. Consult with a financial advisor for personalized advice.